Last updated: August 28, 2026
AMINOSYN II 4.25% with electrolytes in Dextrose 20% with calcium is a parenteral nutrition product used when patients require intravenous amino acids, dextrose, electrolytes, and calcium. Its commercial profile is determined by hospital purchasing, injectable-drug manufacturing capacity, supply continuity, and institutional nutrition protocols rather than by patent exclusivity. Product-level revenue is not publicly reported, and the exact financial trajectory cannot be separated from the broader amino-acid injection and parenteral nutrition portfolios of the manufacturer.
The product is likely a legacy multi-component intravenous nutrition presentation. Its economic value is limited by low differentiation, mature technology, institutional price pressure, and competition from premixed formulations and pharmacy-compounded parenteral nutrition. Its strategic value can rise during shortages because hospitals may need rapid substitutes for unavailable amino-acid or dextrose solutions.
What is AMINOSYN II 4.25% in Dextrose 20% with electrolytes and calcium?
AMINOSYN II is an intravenous amino-acid formulation used as part of parenteral nutrition. The 4.25% amino-acid concentration is combined with 20% dextrose and added electrolytes, including calcium, in a plastic container.
The product is designed to provide:
- Nitrogen and amino acids for protein synthesis.
- Dextrose as a calorie source.
- Electrolyte replacement.
- Calcium supplementation within a parenteral nutrition regimen.
- A ready-to-use base solution that can be further customized under institutional pharmacy protocols.
Parenteral nutrition solutions are generally administered when enteral feeding is contraindicated, inadequate, or not tolerated. Dosing depends on patient weight, metabolic requirements, renal and hepatic function, glucose tolerance, electrolyte levels, and the composition of the broader nutrition regimen. The FDA labeling for amino-acid and dextrose injections emphasizes individualized dosing and monitoring because concentrated dextrose and electrolyte-containing solutions can create risks involving hyperglycemia, fluid balance, metabolic abnormalities, and compatibility [1].
What dosage form and container does AMINOSYN II use?
The specified product is supplied in a plastic container for intravenous use. Plastic packaging is commercially important because parenteral nutrition products must meet requirements involving container integrity, extractables and leachables, oxygen exposure, stability, and compatibility with infusion systems.
The container format supports hospital workflow but does not create significant product differentiation. Competing suppliers also use flexible plastic containers for amino-acid, dextrose, and premixed parenteral nutrition products.
What is the FDA regulatory status of AMINOSYN II?
AMINOSYN II is an older sterile injectable nutrition product rather than a newly developed molecular drug. FDA regulatory treatment depends on the specific presentation, manufacturer, application pathway, and current marketing status.
Products in this category may appear in FDA labeling databases, DailyMed, historical product listings, or drug shortage records even when commercial availability has changed. A label record does not by itself establish that a specific package size is currently marketed.
The principal regulatory risks are manufacturing and quality risks:
- Sterility failure.
- Particulate contamination.
- Incorrect electrolyte concentration.
- Container or closure defects.
- Chemical degradation during storage.
- Production interruptions affecting hospital supply.
- Labeling or packaging changes that require regulatory review.
For mature injectable nutrition products, regulatory compliance and supply reliability generally have greater commercial importance than clinical differentiation.
What patents protect AMINOSYN II?
No meaningful active composition-of-matter patent estate is expected for this legacy amino-acid and dextrose formulation. The active ingredients are established nutrients, and the formulation technology predates the current period of pharmaceutical product innovation.
Potential historical intellectual-property categories include:
| IP category |
Relevance to AMINOSYN II |
| Composition patents |
Likely expired or commercially immaterial |
| Manufacturing patents |
Possible historical protection, but unlikely to block competitors today |
| Container patents |
May apply to packaging systems rather than the specific product |
| Method-of-use patents |
No meaningful exclusivity expected for general parenteral nutrition use |
| Formulation patents |
Any relevant legacy rights are likely expired or non-blocking |
| Orange Book patents |
No publicly evident strategic patent position associated with this legacy product |
The product’s competitive position therefore depends on manufacturing know-how, validated sterile facilities, regulatory history, contracts, and distribution capacity. Those factors can create practical barriers without producing formal patent exclusivity.
Does AMINOSYN II have Orange Book exclusivity?
A commercially significant Orange Book exclusivity position is not expected. The product is not comparable to a recently approved branded drug with a five-year new chemical entity period, three-year clinical-investigation exclusivity, or a listed patent estate supporting Paragraph IV litigation.
The absence of meaningful patent exclusivity shifts competitive risk toward:
- Other approved amino-acid injections.
- Premixed parenteral nutrition systems.
- Pharmacy-compounded formulations.
- Hospital purchasing contracts.
- Temporary shortages and allocation programs.
When does AMINOSYN II lose exclusivity?
The product’s commercial exclusivity has effectively expired because its ingredients, route of administration, and clinical use are longstanding. No future patent cliff is expected to determine market entry.
The relevant commercial timeline is instead:
| Period |
Commercial development |
| Legacy launch period |
Introduction of amino-acid and dextrose parenteral nutrition presentation |
| Mature-market period |
Competition from multiple injectable nutrition suppliers |
| Current period |
Demand determined by hospital contracts, availability, and shortage conditions |
| Future period |
Possible erosion through discontinuation, substitution, or replacement by premixed systems |
This is a market with continuing demand but limited brand pricing power.
How large is the market for injectable parenteral nutrition?
The addressable market includes several overlapping segments:
- Amino-acid injections used as components of individualized nutrition.
- Premixed amino-acid and dextrose solutions.
- Multichamber parenteral nutrition bags.
- Pharmacy-compounded parenteral nutrition.
- Lipid-containing total parenteral nutrition products.
- Pediatric and neonatal nutrition products.
- Specialty formulations for renal, hepatic, or metabolic patients.
AMINOSYN II competes most directly with amino-acid and dextrose products used as building blocks for hospital-compounded parenteral nutrition. It is less directly comparable with multichamber products such as Kabiven or Perikabiven, which incorporate multiple nutrition components and are designed for a different preparation and administration workflow.
Which products compete with AMINOSYN II?
The competitive field includes products from Baxter, B. Braun, Fresenius Kabi, and other suppliers of sterile nutrition products. Relevant competitor categories include:
| Competitor category |
Commercial effect |
| Premixed amino-acid/dextrose solutions |
Reduce pharmacy preparation and labor |
| Electrolyte-containing formulations |
Substitute for products with similar nutrient profiles |
| Multichamber bags |
Offer broader nutrition content in one package |
| Standalone amino-acid injections |
Permit customized institutional compounding |
| Pharmacy-compounded PN |
Can replace commercial bags when hospital capacity is available |
| Therapeutically similar legacy products |
Increase price competition and substitution risk |
The closest practical substitute depends on patient population, required nutrient composition, hospital pharmacy capabilities, available container sizes, and compatibility requirements.
What factors drive AMINOSYN II demand?
Demand is relatively stable but can change sharply during supply disruptions. Key demand drivers include:
Hospital utilization
Demand tracks intensive-care admissions, major surgery, gastrointestinal disease, oncology care, neonatal care, and other conditions requiring prolonged nutritional support. Utilization is institutional rather than retail, so prescribing is influenced by hospital protocols and pharmacy purchasing decisions.
Manufacturing capacity
Sterile injectables require specialized facilities, validated filling lines, quality-control testing, and controlled supply chains. A facility interruption can affect several related products simultaneously.
Shortages
The FDA and the American Society for Health-System Pharmacists have reported recurring shortages involving parenteral nutrition components, amino-acid injections, dextrose solutions, electrolytes, and other sterile injectables [2, 3]. Shortages can temporarily increase demand for available products while reducing revenue if the affected product itself cannot be supplied.
Hospital contracts
Large group purchasing organizations and health systems negotiate aggressively. A product may retain clinical demand while losing volume after a contract change. Contract access is often more important than brand recognition.
Clinical substitution
Hospital pharmacists can substitute among products when nutrient concentrations, electrolyte content, container sizes, and compatibility profiles are acceptable. This limits long-term pricing power.
What is the financial trajectory for AMINOSYN II?
No public company reporting isolates revenue, gross margin, unit volume, or operating profit for the exact AMINOSYN II presentation. A product-level financial model must therefore use market indicators rather than reported brand revenue.
The likely trajectory is:
| Financial factor |
Expected direction |
| Unit demand |
Stable to modestly variable |
| Average selling price |
Low and contract-sensitive |
| Gross margin |
Constrained by commodity inputs and sterile manufacturing costs |
| Revenue growth |
Limited absent shortages or portfolio expansion |
| Pricing power |
Weak |
| Working-capital exposure |
Meaningful because of inventory, shelf life, and allocation |
| Strategic value |
Higher during competitor shortages |
| Long-term risk |
Discontinuation or substitution by newer premixed systems |
Revenue can rise temporarily during a shortage if the manufacturer has available inventory and can secure allocation contracts. That increase may not represent durable market expansion. Conversely, a manufacturing interruption can eliminate sales even when underlying demand remains intact.
The principal cost pressures include amino-acid raw materials, dextrose, electrolytes, plastic containers, sterilization, quality testing, freight, and compliance overhead. Because the product is a high-volume sterile injectable rather than a patented specialty therapy, price increases may be difficult to pass through without contract renegotiation or documented supply constraints.
What generic entry risks exist for AMINOSYN II?
Traditional Paragraph IV litigation risk is low. The relevant competitive threat is product substitution, not patent invalidity.
Potential entrants and substitutes may gain share through:
- Lower contract pricing.
- More reliable supply.
- Broader container-size offerings.
- Better integration with automated compounding systems.
- Reduced pharmacy preparation time.
- Improved availability of compatible electrolyte combinations.
- FDA-authorized alternatives during shortage conditions.
An ANDA applicant could face technical and regulatory requirements involving formulation equivalence, container closure, sterility assurance, stability, and labeling. Those requirements may deter small manufacturers, but they do not provide durable market exclusivity to the incumbent.
What manufacturing and intellectual-property barriers affect the product?
The strongest barriers are operational rather than patent-based. They include:
- FDA-compliant sterile manufacturing capacity.
- Validation of plastic container systems.
- Control of particulate and microbial contamination.
- Reliable procurement of amino acids, dextrose, and electrolytes.
- Stability data across storage and shipping conditions.
- Hospital qualification and purchasing approval.
- Ability to maintain supply across multiple package sizes.
- Compliance with current good manufacturing practice requirements.
These barriers can support a defensible supply position, but they do not necessarily produce high margins. Competitors with comparable facilities can enter if expected volume justifies the investment.
What litigation and settlement activity affects AMINOSYN II?
No major patent litigation or settlement framework is expected to determine the commercial outlook for this product. The product category is more exposed to regulatory enforcement, manufacturing inspections, product recalls, shortage management, and contract disputes than to branded-drug patent litigation.
The absence of patent litigation reduces launch uncertainty for competitors. It also means that any commercial defense must rely on manufacturing reliability, customer relationships, regulatory execution, and pricing.
How does AMINOSYN II compare with newer parenteral nutrition products?
AMINOSYN II has a narrower value proposition than multichamber or lipid-containing parenteral nutrition systems. Its advantages are familiarity, compositional flexibility, and potential usefulness as a base for customized hospital nutrition. Its disadvantages are the need for additional pharmacy manipulation, limited differentiation, and exposure to substitution.
| Attribute |
AMINOSYN II |
Premixed or multichamber PN |
| Customization |
Relatively high when compounded |
Lower for fixed formulations |
| Pharmacy labor |
Higher |
Lower |
| Product complexity |
Lower |
Higher |
| Patent protection |
Minimal |
Product-dependent, generally limited for legacy products |
| Shortage sensitivity |
High |
High |
| Institutional price pressure |
High |
High |
| Clinical differentiation |
Limited |
Workflow and convenience may provide differentiation |
Key Takeaways
- AMINOSYN II 4.25% with electrolytes in Dextrose 20% with calcium is a mature parenteral nutrition product.
- Its market is hospital-based and driven by nutrition protocols, sterile injectable capacity, and supply reliability.
- No meaningful active patent or Orange Book exclusivity is expected to protect the product.
- Paragraph IV litigation and patent settlement risk are low.
- The major commercial threats are competing amino-acid injections, premixed parenteral nutrition, pharmacy compounding, and hospital contract substitution.
- Product-level revenue and profitability are not publicly reported.
- The likely financial profile is stable but low-growth, with temporary upside during shortages and downside from manufacturing interruptions or discontinuation.
- Manufacturing, quality, packaging, and distribution capabilities are more important than intellectual property.
References
-
U.S. Food and Drug Administration. (n.d.). Amino acid and dextrose injection prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.). Drug shortages database. FDA. https://www.accessdata.fda.gov/scripts/drugshortages/
-
American Society of Health-System Pharmacists. (n.d.). Current drug shortages. ASHP. https://www.ashp.org/drug-shortages/current-shortages
-
U.S. National Library of Medicine. (n.d.). DailyMed: AMINOSYN II and parenteral nutrition product labeling. DailyMed. https://dailymed.nlm.nih.gov/dailymed/
